These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 11532286)

  • 1. Membrane-targeted complement inhibitors.
    Smith GP; Smith RA
    Mol Immunol; 2001 Aug; 38(2-3):249-55. PubMed ID: 11532286
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement inhibitors targeted to the proximal tubule prevent injury in experimental nephrotic syndrome and demonstrate a key role for C5b-9.
    He C; Imai M; Song H; Quigg RJ; Tomlinson S
    J Immunol; 2005 May; 174(9):5750-7. PubMed ID: 15843577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human lung cancer cell lines express cell membrane complement inhibitory proteins and are extremely resistant to complement-mediated lysis; a comparison with normal human respiratory epithelium in vitro, and an insight into mechanism(s) of resistance.
    Varsano S; Rashkovsky L; Shapiro H; Ophir D; Mark-Bentankur T
    Clin Exp Immunol; 1998 Aug; 113(2):173-82. PubMed ID: 9717965
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of complement inhibitors in tissue injury.
    Quigg RJ
    Trends Mol Med; 2002 Sep; 8(9):430-6. PubMed ID: 12223314
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum-resistant strains of Borrelia burgdorferi evade complement-mediated killing by expressing a CD59-like complement inhibitory molecule.
    Pausa M; Pellis V; Cinco M; Giulianini PG; Presani G; Perticarari S; Murgia R; Tedesco F
    J Immunol; 2003 Mar; 170(6):3214-22. PubMed ID: 12626580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR/Cas9 generated human CD46, CD55 and CD59 knockout cell lines as a tool for complement research.
    Thielen AJF; van Baarsen IM; Jongsma ML; Zeerleder S; Spaapen RM; Wouters D
    J Immunol Methods; 2018 May; 456():15-22. PubMed ID: 29447841
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of antibody-induced glomerulonephritis with Crry-Ig, a soluble murine complement inhibitor.
    Quigg RJ; Kozono Y; Berthiaume D; Lim A; Salant DJ; Weinfeld A; Griffin P; Kremmer E; Holers VM
    J Immunol; 1998 May; 160(9):4553-60. PubMed ID: 9574562
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the suppressive effects of soluble CR1 and C5a receptor antagonist in acute arthritis induced in rats by blocking of CD59.
    Mizuno M; Nishikawa K; Morgan BP; Matsuo S
    Clin Exp Immunol; 2000 Feb; 119(2):368-75. PubMed ID: 10632677
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Into the third century of complement research.
    Morgan BP; Daha M; Meri S; Nicholson-Weller A
    Immunol Today; 2000 Dec; 21(12):603-5. PubMed ID: 11188795
    [No Abstract]   [Full Text] [Related]  

  • 10. Administration of the soluble complement inhibitor, Crry-Ig, reduces inflammation and aquaporin 4 expression in lupus cerebritis.
    Alexander JJ; Bao L; Jacob A; Kraus DM; Holers VM; Quigg RJ
    Biochim Biophys Acta; 2003 Nov; 1639(3):169-76. PubMed ID: 14636948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Complement inhibition: a new therapeutic modality?].
    Porcel JM
    Med Clin (Barc); 1995 Nov; 105(18):700-2. PubMed ID: 8538252
    [No Abstract]   [Full Text] [Related]  

  • 12. Complement activation on human neuroblastoma cell lines in vitro: route of activation and expression of functional complement regulatory proteins.
    Gasque P; Thomas A; Fontaine M; Morgan BP
    J Neuroimmunol; 1996 May; 66(1-2):29-40. PubMed ID: 8964911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Time course of complement activation and inhibitor expression after ischemic injury of rat myocardium.
    Väkevä A; Morgan BP; Tikkanen I; Helin K; Laurila P; Meri S
    Am J Pathol; 1994 Jun; 144(6):1357-68. PubMed ID: 7515561
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic efficacy of a novel membrane-targeted complement regulator in antigen-induced arthritis in the rat.
    Linton SM; Williams AS; Dodd I; Smith R; Williams BD; Morgan BP
    Arthritis Rheum; 2000 Nov; 43(11):2590-7. PubMed ID: 11083285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. In stroke, the immune system turns traitor.
    Wong K
    US News World Rep; 1999 Aug; 127(5):56. PubMed ID: 10539697
    [No Abstract]   [Full Text] [Related]  

  • 16. Membrane-bound regulators of complement activation in uveal melanomas. CD46, CD55, and CD59 in uveal melanomas.
    Goslings WR; Blom DJ; de Waard-Siebinga I; van Beelen E; Claas FH; Jager MJ; Gorter A
    Invest Ophthalmol Vis Sci; 1996 Aug; 37(9):1884-91. PubMed ID: 8759358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The possibilities and pitfalls for anti-complement therapies in inflammatory diseases.
    Mizuno M; Morgan BP
    Curr Drug Targets Inflamm Allergy; 2004 Mar; 3(1):87-96. PubMed ID: 15032645
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of complement reduces obliterative bronchiolitis.
    Kallio E; Lemström K; Ryan U; Häyry P; Koskinen P
    Transplant Proc; 1999; 31(1-2):188. PubMed ID: 10083071
    [No Abstract]   [Full Text] [Related]  

  • 19. H19, a surface membrane molecule involved in T-cell activation, inhibits channel formation by human complement.
    Whitlow MB; Iida K; Stefanova I; Bernard A; Nussenzweig V
    Cell Immunol; 1990 Mar; 126(1):176-84. PubMed ID: 1689219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).
    Niehans GA; Cherwitz DL; Staley NA; Knapp DJ; Dalmasso AP
    Am J Pathol; 1996 Jul; 149(1):129-42. PubMed ID: 8686736
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.